MedPath

GLYXAMBI

GLYXAMBI

Discontinued
DIN Number

02459752

Drug Class

Human

Market Date

Dec 21, 2016

Company
HC

boehringer ingelheim (canada) ltd ltee

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02459752
AIG Number0258690001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
A10BD19 LINAGLIPTIN AND EMPAGLIFLOZIN
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification68:20.05
Health Canada Classification

ACTIVE INGREDIENTS (2)

EMPAGLIFLOZINActive
Strength: 10 MG
Monograph: EMPAGLIFLOZIN
LINAGLIPTINActive
Strength: 5 MG
Monograph: LINAGLIPTIN

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.